Who
Jeffrey S. Hatfield
Director
Company insider
Files Form 4 as: Director, Vir Biotechnology; Director, Viridian Therapeutics; Director, aTyr Pharma; Chief Executive Officer, Larimar Therapeutics; Director, Invivo Therapeutics Holdings; Chief Executive Officer, Vitae Pharmaceuticals; Director, Ambit Biosciences.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.4M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 2 Jun 2014
- Last trade
- 27 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 22 May 2023filed 24 May 2023 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,054 at $0.00 | filing |
| 22 May 2023filed 24 May 2023 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —6,027 at $0.00 | filing |
| 23 May 2022filed 25 May 2022 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,810 at $0.00 | filing |
| 23 May 2022filed 25 May 2022 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 21 May 2021filed 25 May 2021 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —3,374 at $0.00 | filing |
| 21 May 2021filed 25 May 2021 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,748 at $0.00 | filing |
| 4 Feb 2021filed 8 Feb 2021 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Dec 2020filed 11 Dec 2020 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,500 at $0.00 | filing |
| 21 May 2020filed 22 May 2020 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 May 2020filed 8 May 2020 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,428 at $0.00 | filing |
| 19 Jun 2019filed 21 Jun 2019 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 8 May 2019filed 10 May 2019 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.